Immunogenicity of Human Neuroblastoma
- 1 December 2004
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1028 (1) , 69-80
- https://doi.org/10.1196/annals.1322.008
Abstract
Neuroblastoma (NB) is a neuroectodermal tumor that affects children in the first years of life. Half of NB cases present with metastatic disease at diagnosis and have a poor prognosis, in spite of the most advanced chemotherapeutic protocols combined with autologous hematopoietic stem cell transplantation. Among the new avenues for NB treatment that are being explored, immunotherapy has attracted much interest. Emphasis has been placed on monoclonal antibodies directed to tumor‐associated antigens—in particular the disialoganglioside GD2—that have been tested in the clinical setting with promising results. In addition, stimulation of cell‐mediated antitumor effector mechanisms have been attempted—for example, by recombinant interleukin (IL)‐2 administration. Nonetheless, the issue of the immunogenicity of human NB cells has never been thoroughly addressed. Here we shall review the work carried out in our lab in recent years and show that NB cells express tumor‐associated antigens, such as MAGE‐3, but lack constitutive expression of costimulatory molecules and surface HLA class I and II molecules. As such, NB cells are likely to be ignored by the host T cell compartment, since expression of HLA and costimulatory molecules on antigen presenting cells are sine qua non conditions for efficient peptide presentation to T cells and for the subsequent activation and clonal expansion of the latter cells. Notably, in vitro experiments with NB cell lines demonstrated that surface HLA class I molecules and the CD40 costimulatory molecule were upregulated following cell incubation with recombinant interferon‐γ. Interaction of CD40 with recombinant CD40 ligand induced apoptosis of NB cells through a caspase 8‐dependent mechanism. Collectively, these results indicate that the immunogenicity of human NB cells is very low but suggest that manipulation by cytokine administration or gene transfer can increase their immunogenic potential. On the other hand, NB cells represent an excellent target for natural killer cells, the potential role of which in immunotherapy of NB is now being investigated.Keywords
This publication has 28 references indexed in Scilit:
- Paraneoplastic Syndromes Involving the Nervous SystemNew England Journal of Medicine, 2003
- HLA class I antigen abnormalities and immune escape by malignant cellsSeminars in Cancer Biology, 2002
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- Ultrastructural and Functional Studies of the Interaction between IL-12 and IL-2 for the Generation of Lymphokine-Activated Killer CellsExperimental Cell Research, 1999
- A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastomaCancer, 1997
- Major histocompatibility complex class I‐specific receptors on human natural killer and T lymphocytesImmunological Reviews, 1997
- A reassessment of the role of B7-1 expression in tumor rejection.The Journal of Experimental Medicine, 1995
- Neuroblastoma Cell-Mediated Leukocyte Chemotaxis: Lineage-Specific Differentiation of Interleukin-8 ExpressionExperimental Cell Research, 1994
- Letter to the editorInternational Journal of Cancer, 1993
- Human T-cell subsets in health and diseaseSpringer Seminars in Immunopathology, 1984